Maze Therapeutics, Inc. (MAZE)
22.52
-0.92
(-3.92%)
USD |
NASDAQ |
Sep 18, 16:00
22.61
+0.09
(+0.40%)
Pre-Market: 20:00
Maze Therapeutics Enterprise Value : 899.30M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 899.30M |
| September 17, 2026 | 950.36M |
| September 16, 2026 | 976.73M |
| September 15, 2026 | 994.21M |
| September 14, 2026 | 1.019B |
| September 11, 2026 | 1.015B |
| September 10, 2026 | 1.027B |
| September 09, 2026 | 1.014B |
| September 08, 2026 | 1.113B |
| September 04, 2026 | 1.104B |
| September 03, 2026 | 1.085B |
| September 02, 2026 | 1.132B |
| September 01, 2026 | 1.122B |
| August 31, 2026 | 1.124B |
| August 28, 2026 | 1.172B |
| August 27, 2026 | 1.237B |
| August 26, 2026 | 1.291B |
| August 25, 2026 | 1.338B |
| August 24, 2026 | 1.292B |
| August 21, 2026 | 1.283B |
| August 20, 2026 | 1.255B |
| August 19, 2026 | 1.301B |
| August 18, 2026 | 1.266B |
| August 17, 2026 | 1.201B |
| August 14, 2026 | 1.158B |
| Date | Value |
|---|---|
| August 13, 2026 | 1.185B |
| August 12, 2026 | 1.177B |
| August 11, 2026 | 1.165B |
| August 10, 2026 | 1.164B |
| August 07, 2026 | 1.240B |
| August 06, 2026 | 1.233B |
| August 05, 2026 | 1.193B |
| August 04, 2026 | 1.182B |
| August 03, 2026 | 1.166B |
| July 31, 2026 | 1.144B |
| July 30, 2026 | 1.183B |
| July 29, 2026 | 1.163B |
| July 28, 2026 | 1.197B |
| July 27, 2026 | 1.242B |
| July 24, 2026 | 1.186B |
| July 23, 2026 | 1.186B |
| July 22, 2026 | 1.231B |
| July 21, 2026 | 1.276B |
| July 20, 2026 | 1.224B |
| July 17, 2026 | 1.210B |
| July 16, 2026 | 1.157B |
| July 15, 2026 | 1.281B |
| July 14, 2026 | 1.308B |
| July 13, 2026 | 1.269B |
| July 10, 2026 | 1.346B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.984B |
| Corcept Therapeutics, Inc. | 11.60B |
| Veru, Inc. | 17.98M |
| Johnson & Johnson | 678.48B |
| Eli Lilly & Co. | 1.131T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.73M |
| Total Expenses (Quarterly) | 44.73M |
| EPS Diluted (Quarterly) | -0.7581 |
| Earnings Yield | -11.25% |
| Normalized Earnings Yield | -11.26 |